Supernus Announces Second Quarter 2021 Financial Results
- Second quarter 2021 total revenues of
$141.3 million, a 12% increase compared to 2020
- Qelbree™ launched in the
U.S.for pediatric ADHD at the end of May 2021
- Qelbree sNDA for adult ADHD submitted to the FDA
- SPN-830 (apomorphine infusion pump) NDA resubmission anticipated in the second half of 2021
“The approval and commercial launch of Qelbree for pediatric patients with ADHD mark an important milestone for children and families searching for new treatment options for ADHD,” said
Net Product Sales
Second quarter 2021 net product sales were
|Net Product Sales|
|($ in millions)||Q2 2021||Q2 2020 (1)||Change %|
|Net Product Sales||$||138.6||$||124.0||12||%|
(1) Net product sales of APOKYN, MYOBLOC and XADAGO from
Qelbree Launch Update
- At the end of
May 2021, Supernus launched Qelbree for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age. Net product sales for the second quarter of 2021 were $0.3 million.
- The early performance of Qelbree is on track with our expectations. Current trends in prescriptions reflect the heavy sampling programs with patients. Over 25,000 starter kits have been distributed to physicians since the launch and in preparation for the back-to-school season.
- Early clinical feedback about the performance of Qelbree in patients is positive and in line with the Phase III clinical results.
Product Pipeline Update
Qelbree (viloxazine, extended-release capsules) - Novel non-stimulant for the treatment of ADHD in adults
- The Company recently submitted a supplemental New Drug Application (sNDA) to the
U.S. Food and Drug Administration(FDA) for Qelbree for adult patients with ADHD.
SPN-830 (apomorphine infusion pump) - Continuous treatment of motor fluctuations (“on-off” episodes) in Parkinson's disease (PD)
- The Company continues to plan to resubmit the SPN-830 NDA in the second half of 2021.
SPN-820 - Novel first-in-class activator of mTORC1
- A randomized Phase II clinical study of SPN-820 in treatment-resistant depression is expected to start by the end of 2021.
Second quarter 2021 operating earnings were
Second quarter 2021 net earnings and diluted earnings per share were
Full Year 2021 Financial Guidance
For full year 2021, the Company reiterates its prior financial guidance including an increase to the lower end of its operating earnings guidance as set forth below:
|Full Year 2021 Guidance
($ in millions)
|Total revenues (1)|
|Combined R&D and SG&A expenses (2)|
|Operating earnings (3)|
|Amortization of intangible assets|
|Effective tax rate(4)||28% - 31%|
(1) Total revenues include net product sales and royalty revenue. Includes $10 million for Qelbree net product sales.
(2) Combined research and development and selling, general and administrative expenses.
(3) Operating earnings include amortization of intangible assets and contingent consideration expense (gain). Reflects an increase from the original guidance of
(4) The full year 2021 effective tax rate guidance of 28% - 31% is above the normally expected range of 26% - 28% due to the effect of discrete tax items in the period.
Conference Call Details
The Company will hold a conference call hosted by
Please refer to the information below for conference call dial-in information and webcast registration. Callers should dial in approximately 10 minutes prior to the start of the call.
|Conference dial-in:||(877) 288-1043|
|International dial-in:||(970) 315-0267|
|Conference Call Name:||Supernus Pharmaceuticals Second Quarter 2021 Results Conference Call|
Following the live call, a replay will be available on the Company's website, www.supernus.com, under “Investor Relations”.
Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease, cervical dystonia and chronic sialorrhea. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in Parkinson’s disease, epilepsy, depression and rare CNS disorders.
For more information, please visit www.supernus.com.
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company’s ability to sustain and increase its profitability; the Company’s ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company’s corporate strategy; the Company’s future financial performance and projected expenditures; the Company’s ability to increase the number of prescriptions written for each of its products; the Company’s ability to increase its net revenue; the Company’s ability to commercialize its products including Qelbree; the Company’s ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company’s product research and development activities, including the timing and progress of the Company’s clinical trials, and projected expenditures; the Company’s ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company’s product candidates; the Company’s ability to protect its intellectual property and operate its business without infringing upon the intellectual property rights of others; the Company’s expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company’s product candidates; the accuracy of the Company’s estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company’s ability to increase its manufacturing capabilities for its products and product candidates; the Company’s projected markets and growth in markets; the Company’s product formulations and patient needs and potential funding sources; the Company’s staffing needs; and other risk factors set forth from time to time in the Company’s filings with the
Condensed Consolidated Balance Sheets
(in thousands, except share data)
|Cash and cash equivalents||$||223,771||$||288,640|
|Accounts receivable, net||137,275||140,877|
|Prepaid expenses and other current assets||33,737||18,682|
|Total current assets||639,244||630,417|
|Long term marketable securities||445,473||350,359|
|Property and equipment, net||17,065||37,824|
|Intangible assets, net||352,628||364,342|
|Liabilities and stockholders’ equity|
|Accounts payable and accrued liabilities||$||79,993||$||78,934|
|Accrued product returns and rebates||173,598||126,192|
|Contingent consideration, current portion||23,540||30,900|
|Other current liabilities||6,316||9,082|
|Total current liabilities||283,447||245,108|
|Convertible notes, net||370,383||361,751|
|Contingent consideration, long term||45,430||45,800|
|Operating lease liabilities, long term||36,143||28,579|
|Deferred income tax liabilities||32,986||35,215|
|Additional paid-in capital||424,175||409,332|
|Accumulated other comprehensive earnings, net of tax||5,433||8,975|
|Total stockholders’ equity||785,579||744,858|
|Total liabilities and stockholders’ equity||$||1,573,060||$||1,504,102|
Condensed Consolidated Statements of Earnings
(in thousands, except share and per share data)
|Three Months ended
||Six Months ended
|Net product sales||$||138,628||$||123,984||$||267,009||$||216,474|
|Costs and expenses|
|Cost of goods sold (a)||25,028||8,386||39,982||12,538|
|Research and development||15,455||22,247||49,735||41,184|
|Selling, general and administrative||69,535||48,103||130,992||89,717|
|Amortization of intangible assets||5,948||2,445||11,955||3,706|
|Contingent consideration gain||(8,750||)||—||(7,730||)||—|
|Total costs and expenses||107,216||81,181||224,934||147,145|
|Other income (expense)|
|Interest and other income, net||2,589||7,477||6,401||13,254|
|Total other income (expense)||(2,878||)||1,662||(5,163||)||1,684|
|Earnings before income taxes||31,235||47,210||42,164||76,244|
|Income tax expense||7,509||12,543||12,744||20,059|
|Earnings per share|
|Weighted-average shares outstanding|
(a) Excludes amortization of acquired intangible assets
Tel: (301) 838-2591
Office: (443) 213-0505
Mobile: (443) 377-4767
Source: Supernus Pharmaceuticals, Inc.